The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
The era of cryptic exons: implications for ALS-FTD
Translational molecular imaging and drug development in Parkinson’s disease
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Common mouse models of tauopathy reflect early but not late human disease
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients